Christos Tzivinikos
Overview
Explore the profile of Christos Tzivinikos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cohen S, Spencer E, Dolinger M, Suskind D, Mitrova K, Hradsky O, et al.
Aliment Pharmacol Ther
. 2025 Feb;
PMID: 39921898
Background: There are scarce data available on upadacitinib in children with Crohn's disease (CD). Aim: To evaluate the effectiveness and safety of upadacitinib as an induction therapy in paediatric CD....
2.
Weintraub Y, Collen L, Hussey S, Mitrova K, Machta J, Kang B, et al.
Inflamm Bowel Dis
. 2025 Jan;
PMID: 39813158
Background And Aims: Patients with very early-onset inflammatory bowel disease (VEO-IBD), with an age of onset < 6 years, can present with severe manifestations and may require biologic therapy. Infliximab...
3.
Broekaert I, Assa A, Borrelli O, Saccomani M, Homan M, Martin-de-Carpi J, et al.
J Pediatr Gastroenterol Nutr
. 2025 Jan;
80(3):510-532.
PMID: 39783775
Anaemia is a frequent consequence of many gastrointestinal (GI) diseases in children and it can even be the initial presenting symptom of underlying chronic GI disease. The definition of anaemia...
4.
Yerushalmy-Feler A, Spencer E, Dolinger M, Suskind D, Mitrova K, Hradsky O, et al.
J Crohns Colitis
. 2024 Nov;
PMID: 39605286
Background And Aims: Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of...
5.
Alsarhan A, Hamdi M, Golightly K, Tzivinikos C
Cureus
. 2024 Oct;
16(9):e69537.
PMID: 39416532
Achalasia is uncommon in pediatrics and typically presents after five years of age. It is often managed medically, endoscopically, or surgically such as myectomy. This case highlights an exceptionally rare...
6.
Homan M, Thomson M, Bontems P, Saccomani M, Amil Dias J, Faraci S, et al.
J Pediatr Gastroenterol Nutr
. 2024 Sep;
79(6):1096-1105.
PMID: 39315663
No abstract available.
7.
Guz-Mark A, Aloi M, Scarallo L, Bramuzzo M, Escher J, Alvisi P, et al.
Pediatrics
. 2024 Jul;
154(2.
PMID: 39015095
Objectives: This study described disease characteristics and long-term outcomes in patients diagnosed with very early onset inflammatory bowel disease (VEOIBD) (diagnosed before 6 years of age) and infantile-IBD (before 2...
8.
Amil-Dias J, Oliva S, Papadopoulou A, Thomson M, Gutierrez-Junquera C, Kalach N, et al.
J Pediatr Gastroenterol Nutr
. 2024 Jun;
79(2):394-437.
PMID: 38923067
Introduction: Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus characterized by symptoms of esophageal dysfunction and histologically by predominantly eosinophilic infiltration of the squamous epithelium. European Society...
9.
Ledder O, Dolinger M, Dubinsky M, Stein R, Vellanki S, Buckuk R, et al.
Inflamm Bowel Dis
. 2024 Jun;
31(2):425-431.
PMID: 38828483
Background: Tofacitinib has recently been approved for treatment of moderate-to-severe ulcerative colitis (UC) in adults, yet pediatric data are limited. This international multicenter study describes the effectiveness and safety of...
10.
Cohen S, Rolandsdotter H, Kolho K, Turner D, Tzivinikos C, Bramuzzo M, et al.
Paediatr Drugs
. 2024 May;
26(5):609-617.
PMID: 38780740
Background And Objectives: Current data on ustekinumab therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBDU) are limited. We aimed to evaluate the effectiveness and safety...